浙江时迈药业有限公司

Q: What does 浙江时迈药业有限公司 do?

以患者和临床需求为己任

浙江时迈药业有限公司

以患者和临床需求为己任

Founded 2017 China

China 4 employees Series A Biotechnology, Health Care +3

Centrymed is a biotechnology startup founded in 2017 that focuses on innovative solutions in tumor treatment. The company's slogan "Innovative solutions in tumor treatment leveraging a proprietary dual-antibody platform to address drug stability and minimize side effects" encapsulates its mission. Centrymed has developed a proprietary dual-antibody platform to address issues related to the drug's effectiveness and the toxic side effects commonly associated with antibody medications. The startup recently secured a Series A investment on 09 February 2022, with participation from a group of notable investors including Yxassets.com, Hongxin Venture Capital CO. LTD., Betta Pharmaceuticals, Anji Maisheng, Chenghe Venture Capital, Binjiang District Government Fund Hang Gao Investment, Taikun Capital, and Guangzhou Yue Min Investment. Centrymed's focus on addressing critical issues in tumor treatment and its ability to attract a diverse group of investors highlight the promise and potential of the startup. The innovative nature of its proprietary dual-antibody platform positions Centrymed as a noteworthy player in the biotechnology and healthcare industries. This recent investment provides the company with the necessary resources to further develop its cutting-edge solutions and make a significant impact in the field of tumor treatment.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	Undisclosed	8	Yxassets.com, Hongxin Venture Capital CO. LTD. +6	09 Feb 2022
Series A	Undisclosed	2	Yip's Chemical Holdings, TaiKun Fund	01 Jan 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

Undisclosed

Yxassets.com, Hongxin Venture Capital CO. LTD. +6

09 Feb 2022

Series A

Undisclosed

Yip's Chemical Holdings, TaiKun Fund

01 Jan 2022

FAQ About 浙江时迈药业有限公司

以患者和临床需求为己任

浙江时迈药业有限公司 was founded in 2017.

浙江时迈药业有限公司 is headquartered in China.

浙江时迈药业有限公司 operates in Biotechnology, Health Care, Manufacturing, Medical Devices and Pharmaceutical. Its work centres on Tumor treatment, Dual-antibody platform, Drug stability and Side effects minimization.

浙江时迈药业有限公司 has approximately 4 employees.

浙江时迈药业有限公司 has completed 2 funding rounds. The latest funding stage is Series A.

Top alternatives and competitors to 浙江时迈药业有限公司 include KangaBio, Shasqi, Rexahn Pharmaceuticals, LeadInvent Pharma Inc., Strike Pharma AB. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

浙江时迈药业有限公司 and KangaBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About 浙江时迈药业有限公司

Funding Rounds & Investors (2)

浙江时迈药业有限公司 Alternatives & Competitors

FAQ About 浙江时迈药业有限公司